Why and how immunohistochemistry should now be used to screen for the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France)-Reference-Cited by-同舟云学术

Why and how immunohistochemistry should now be used to screen for the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France)

Published:2015-09-16 Issue:12 Volume:29 Page:2436-2443
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Long E.¹²,Ilie M.¹²,Lassalle S.¹²,Butori C.¹,Poissonnet G.³,Washetine K.¹⁴,Mouroux J.²⁵,Lespinet V.¹,Lacour J.P.⁶,Taly V.⁷,Laurent-Puig P.⁷,Bahadoran P.⁶,Hofman V.¹²⁴,Hofman P.¹²⁴

Affiliation:

1. Laboratory of Clinical and Experimental Pathology; Pasteur Hospital; Nice Cedex France

2. Institute for Research on Cancer and Aging; Nice (IRCAN) CNRS UMR 7284/Inserm U1081; University of Nice Sophia Antipolis; Nice France

3. Department of Surgery; CLCC Antoine Lacassagne Center; Nice France

4. Nice Hospital-Related Biobank BB-0033-00025; Pasteur Hospital; Nice France

5. Department of Thoracic Surgery; Pasteur Hospital; Nice France

6. Department of Dermatology; Archet Hospital; Nice France

7. INSERM UMR-S1147; Centre Universitaire des Saints-Pères; University Paris Sorbonne Cité; Paris France

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.13332/fullpdf

Reference30 articles.

1. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma;Colombino;J Clin Oncol,2013

2. BRAF in melanoma: current strategies and future directions;Salama;Clin Cancer Res,2013

3. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032;Rubinstein;J Transl Med,2010

4. Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing;Boursault;PLoS ONE,2013

5. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions;Busam;Am J Surg Pathol,2013

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Principles of Analytic Validation of Immunohistochemical Assays: Guideline Update;Archives of Pathology & Laboratory Medicine;2024-02-23

2. Comparison of Two Rapid Assays for the Detection of BRAF V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes;Diagnostics;2022-03-19

3. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting;Pathology;2022-02

4. The Histopathology of Melanocytic Nevi and Malignant Melanoma;Melanoma in Clinical Practice;2021

5. PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome;International Journal of Molecular Sciences;2020-11-30